LIXTE Biotechnology, a publicly traded company in the U.S., has launched a cryptocurrency reserve strategy, planning to allocate 25% of its funds to BTC

2025-08-13 20:02:06

Collection

ChainCatcher news, Nasdaq-listed company LIXTE Biotechnology announced that its board has approved a strategic capital allocation plan to acquire cryptocurrency as part of the company's funds. The company's board also approved allocating 25% of the funds to cryptocurrency, including Bitcoin and other potential digital assets (as applicable).

source

warnning

Risk warning

Related tags

LIXTE Biotechnology Bitcoin

Related reading

The founder of Strategy claims that the decline in BTC is due to the rotation of funds into AI rather than "issues with Bitcoin itself," and JPMorgan warns that the legislative window for the CLARITY Act is closing

2026-06-05 10:09

Analysis: The Bitcoin engine of Strategy has malfunctioned, putting pressure on all three types of investors

2026-06-05 09:16

Chainalysis: Gray market peptide suppliers are rapidly shifting to Bitcoin and stablecoins, with a year-on-year surge of 159% in crypto inflows in Q1

2026-06-05 08:24

Beisent: The U.S. Strategic Bitcoin Reserve Plan is steadily advancing

2026-06-04 20:27

Related tags

LIXTE Biotechnology Bitcoin

app_icon

ChainCatcher Building the Web3 world with innovations.